Meta-analysis Of Cyclin-dependent Kinase 4/6 Inhibitors In The Treatment Of Breast Cancer With Low Risk Of Immunity

Objective: To systematic review and evaluate the safety of cyclin-dependent kinase 4/6 inhibitors as first-line therapeutic agents for breast cancer using meta-analysis.Methods: Databases such as Pubmed,Embase,and Cochrane library were searched by computer to search literature on cyclin-dependent kinase 4/6 inhibitors published in English from January 2010 to December 2017 for the treatment of breast cancer.Randomized controlled trials(RC Ts),interventions,etc.were included in the exclusion criteria screening literature,and relevant data were extracted.Meta analysis of the data was performed using Rev Man 5.3 software to determine whether the use of CDK4/6 inhibitors in the treatment of breast cancer increased the risk of low immunity.Evaluation.Results: Six clinical randomized controlled trials of phase II and III were included.Meta-analysis showed that the use of cyclin-dependent kinase 4/6 inhibitors in the treatment of breast cancer was associated with an increased incidence of grade 3,grade 3,and grade 4 neutropenia,with incidence of all grades and grade 3 leukopenia Increased correlations are associated with increased incidence of stomatitis and upper respiratory infections at all levels.However,there was no statistically significant difference between the experimental group and the control group in terms of grade 3 leukopenia,high grade(including grades 3 and 4)stomatitis,and incidence of upper respiratory tract infections.Conclusion: The use of CDK4/6 inhibitors is associated with an increased incidence of neutropenia,leukopenia,stomatitis,and upper respiratory tract infection,but it cannot be considered with high grade(grades 3 and 4)stoma titis and upper respiratory tract.The occurrence of infection is related.Since the inhibition of bone marrow function by cyclin-dependent kinase 4/6 inhibitors is reversible,although the incidence of low-immune events increases,there is no toxic accumulation effect,so when the toxic side effects are serious but the clinical application can be effective By continuing the treatment by reducing the drug dose,there is no need to stop the drug and cause unnecessary loss.